Society for Neuro-Oncology Annual Meeting | Conference

Survival Improvement With NovoTTF Leads to Early End of Phase III Trial

November 16th 2014

Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.

Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBM

November 16th 2014

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).

Rindopepimut Leads to Improved PFS in Compassionate Use Study

November 16th 2014

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

Dr. van den Bent Discusses Bevacizumab Plus Lomustine in Recurrent Glioblastoma

November 15th 2014

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.

Ceritinib Effective in Patients With Brain Metastases

November 15th 2014

The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.

Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in Glioblastoma

November 15th 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.

Rindopepimut Plus Bevacizumab Shows Prolonged Survival in Recurrent Glioblastoma

November 15th 2014

The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

Adding Lomustine to Bevacizumab Improves Outcomes in Recurrent Glioblastoma

November 14th 2014

The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.

Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade Gliomas

November 14th 2014

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

PCV Chemotherapy Plus Radiation Improves Survival in Low-Grade Glioma

November 14th 2014

The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.

Dr. Toms on Targeting MEK as a Treatment Strategy for CNS Metastasis

November 14th 2014

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.